<DOC>
	<DOC>NCT00234338</DOC>
	<brief_summary>The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.</brief_summary>
	<brief_title>Study Evaluating Prevenar in High-Risk Children</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Highrisk children ages 2 to 5 years old Exclusion criteria: Prior administration of Prevenar Prior and/or concurrent administration of 23 vPs vaccine</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Children</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Prevenar</keyword>
</DOC>